Somatostatin Analogs – our new study reveals trends, R&D progress, and predicted revenues
Where is the Somatostatin Analogs market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2029, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 253-page report provides 38 tables, 273 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Somatostatin Analogs market. See how to exploit the opportunities.
Forecasts to 2029 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2029, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are 2 segmentations of the Somatostatin Analogs market, with forecasts for 3 Types and 2 Indication, each forecasted at a global and regional level.
Global Somatostatin Analogs Market by Type
• Octreotide
• Lanreotide
• Pasireotide
Global Somatostatin Analogs Market by Indication
• Neuroendocrine Tumor (NET)
• Acromegaly
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 7 regional and 17 leading national markets:
• North America:
• US
• Canada
• Latin America:
• Brazil
• Mexico
• Rest of Latin America
• Western Europe:
• Germany
• The UK
• Italy
• France
• Spain
• Nordic
• Benelux
• Rest of Western Europe
• Eastern Europe:
• Russia
• Poland
• Rest of Eastern Europe
• Asia-Pacific:
• Japan
• China
• India
• Australia & New Zealand
• ASEAN
• Rest of Asia-Pacific
• MEA:
• GCC Countries
• South Africa
• Northern Africa
• Rest of MEA
The report also includes profiles and for some of the leading companies in the Somatostatin Analogs market, with a focus on this segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Russia, Germany and China in particular, will continue to achieve high revenue growth to 2029.
Leading companies and the potential for market growth
Overall world revenue for Somatostatin Analogs will surpass $2.87 billion in 2019, our work calculates. We predict strong revenue growth through to 2029.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Somatostatin Analogs Market report helps you
In summary, our 253-page report provides you with the following knowledge:
• Revenue forecasts to 2029 for 2 segmentations of the Somatostatin Analogs market, with forecasts for 3 Types and 2 Indication, each forecasted at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2029 for 6 regional and 21 key national markets – See forecasts for the Somatostatin Analogs market in North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, the UK, Italy, France, Nordic Countries, Benelux, China, India, Japan, Australia & New Zealand, ASEAN countries, GCC Countries, South Africa and Northern Africa.
• Stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the Somatostatin Analogs market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the Somatostatin Analogs Sequencing market and leading companies. You will find data, trends and predictions.
Get our report today The Somatostatin Analogs Market Forecast 2019-2029: Revenue Prospects by Type (Octreotide, Lanreotide, Pasireotide), Indication (Neuroendocrine Tumor (NET), Acromegaly), and Geography.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Somatostatin Analogs Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Global Somatostatin Analogs Market Size and Forecast
2.3. Market Dynamics
2.3.1. Market Drivers
2.3.2. Market Restraints
2.3.3. Market Opportunities
2.3.4. Global Somatostatin Analogs Market: Trends
2.3.5. Mergers and Acquisitions
2.3.6. Entry of New Market Players
3. Global Somatostatin Analogs Market Analysis and Forecast, By Type
3.1. Introduction
3.1.1. Global Somatostatin Analogs Market, Annual Growth Rate Comparison, By Type
3.2. Global Somatostatin Analogs Market Size and Forecast, By Type
3.2.1. Octreotide
3.2.2. Lanreotide
3.2.3. Pasireotide
3.3. Global Somatostatin Analogs Attractiveness Index, By Type
4. Global Somatostatin Analogs Market Analysis and Forecast, By Indication
4.1. Introduction
4.1.1. Global Somatostatin Analogs Market, Annual Growth Rate Comparison, By Indication
4.1.2. Global Somatostatin Analogs Market Share Comparison, By Indication (2018 & 2029)
4.2. Global Somatostatin Analogs Market Size and Forecast, By Indication
4.2.1. Neuroendocrine Tumor (NET)
4.2.2. Acromegaly
4.3. Global Somatostatin Analogs Attractiveness Index, By Indication
5. Global Somatostatin Analogs Market Analysis and Forecast, By Region
5.1. Introduction
5.1.1. Global Somatostatin Analogs Market, Annual Growth Rate Comparison, By Region
5.1.2. Global Somatostatin Analogs Market Share Comparison, By Region (2018 & 2029)
5.2. Global Somatostatin Analogs Market Size and Forecast, By Region
5.2.1. North America (U.S., Canada)
5.2.2. Latin America (Brazil, Mexico, Rest of Latin America)
5.2.3. Western Europe (UK, France, Germany, Italy, Spain, Nordic, Benelux, RoWE)
5.2.4. Eastern Europe (Russia, Poland, Rest of Eastern Europe)
5.2.5. Asia Pacific (Japan, China, India, ASEAN, Australia, RoAPAC)
5.2.6. MEA (GCC, South Africa, North Africa, RoMEA)
5.3. Global Somatostatin Analogs Market Attractiveness Index, By Region
6. North America Somatostatin Analogs Market Analysis and Forecast, 2019–2029
6.1. Introduction
6.1.1. North America Somatostatin Analogs Market
6.1.2. North America Somatostatin Analogs Market, Annual Growth Rate Comparison, By Country
6.2. North America Somatostatin Analogs Market Size and Forecast, By Country
6.2.1. The U.S. Somatostatin Analogs Market
6.2.2. Canada Somatostatin Analogs Market
6.3. North America Somatostatin Analogs Market Size and Forecast, By Type
6.4. North America Somatostatin Analogs Market Size and Forecast, By Indication
6.5. North America Somatostatin Analogs Market Attractiveness Index
6.6. North America Somatostatin Analogs Market Attractiveness Index, By Country
6.7. North America Somatostatin Analogs Market Attractiveness Index, By Type
6.8. North America Somatostatin Analogs Market Attractiveness Index, By Indication
7. Latin America Somatostatin Analogs Market Analysis and Forecast, 2019–2029
7.1. Introduction
7.1.1. Latin America Somatostatin Analogs Market
7.1.2. Latin America Somatostatin Analogs Market, Annual Growth Rate Comparison, By Country
7.2. Latin America Somatostatin Analogs Market Size and Forecast, By Country
7.2.1. Brazil Somatostatin Analogs Market
7.2.2. Mexico Somatostatin Analogs Market
7.2.3. Rest of Latin America Somatostatin Analogs Market
7.3. Latin America Somatostatin Analogs Market Size and Forecast, By Type
7.4. Latin America Somatostatin Analogs Market Size and Forecast, By Indication
7.5. Latin America Somatostatin Analogs Market Attractiveness Index
7.6. Latin America Somatostatin Analogs Market Attractiveness Index, By Country
7.7. Latin America Somatostatin Analogs Market Attractiveness Index, By Type
7.8. Latin America Somatostatin Analogs Market Attractiveness Index, By Indication
8. Western Europe Somatostatin Analogs Market Analysis and Forecast, 2019–2029
8.1. Introduction
8.1.1. Western Europe Somatostatin Analogs Market
8.1.2. Western Europe Somatostatin Analogs Market, Annual Growth Rate Comparison, By Country
8.2. Western Europe Somatostatin Analogs Market Size and Forecast, By Country
8.2.1. U.K. Somatostatin Analogs Market
8.2.2. France Somatostatin Analogs Market
8.2.3. Germany Somatostatin Analogs Market
8.2.4. Italy Somatostatin Analogs Market
8.2.5. Spain Somatostatin Analogs Market
8.2.6. Nordic Somatostatin Analogs Market
8.2.7. Benelux Somatostatin Analogs Market
8.2.8. Rest of Western Europe Somatostatin Analogs Market
8.3. Western Europe Somatostatin Analogs Market Size and Forecast, By Type
8.4. Western Europe Somatostatin Analogs Market Size and Forecast, By Indication
8.5. Western Europe Somatostatin Analogs Market Attractiveness Index
8.6. Western Europe Somatostatin Analogs Market Attractiveness Index, By Country
8.7. Western Europe Somatostatin Analogs Market Attractiveness Index, By Type
8.8. Western Europe Somatostatin Analogs Market Attractiveness Index, By Indication
8.9. Western Europe Somatostatin Analogs Market Attractiveness Index, By Segment 3
8.10. Western Europe Somatostatin Analogs Market Attractiveness Index, By Segment 4
8.11. Western Europe Somatostatin Analogs Market Attractiveness Index, By Segment 5
8.12. Western Europe Somatostatin Analogs Market Attractiveness Index, By Segment 6
8.13. Western Europe Somatostatin Analogs Market Attractiveness Index, By Segment 7
9. Eastern Europe Somatostatin Analogs Market Analysis and Forecast, 2019–2029
9.1. Introduction
9.1.1. Eastern Europe Somatostatin Analogs Market
9.1.2. Eastern Europe Somatostatin Analogs Market, Annual Growth Rate Comparison, By Country
9.2. Eastern Europe Somatostatin Analogs Market Size and Forecast, By Country
9.2.1. Russia Somatostatin Analogs Market
9.2.2. Poland Somatostatin Analogs Market
9.2.3. Rest of Eastern Europe Somatostatin Analogs Market
9.3. Eastern Europe Somatostatin Analogs Market Size and Forecast, By Type
9.4. Eastern Europe Somatostatin Analogs Market Size and Forecast, By Indication
9.5. Eastern Europe Somatostatin Analogs Market Attractiveness Index
9.6. Eastern Europe Somatostatin Analogs Market Attractiveness Index, By Country
9.7. Eastern Europe Somatostatin Analogs Market Attractiveness Index, By Type
9.8. Eastern Europe Somatostatin Analogs Market Attractiveness Index, By Indication
10. Asia Pacific Somatostatin Analogs Market Analysis and Forecast, 2019–2029
10.1. Introduction
10.1.1. Asia Pacific Somatostatin Analogs Market
10.1.2. Asia Pacific Somatostatin Analogs Market, Annual Growth Rate Comparison, By Country
10.2. Asia Pacific Somatostatin Analogs Market Size and Forecast, By Country
10.2.1. China Somatostatin Analogs Market
10.2.2. India Somatostatin Analogs Market
10.2.3. Australia Somatostatin Analogs Market
10.2.4. ASEAN Somatostatin Analogs Market
10.2.5. Japan Somatostatin Analogs Market
10.2.6. Rest of Asia Pacific Somatostatin Analogs Market
10.3. Asia Pacific Somatostatin Analogs Market Size and Forecast, By Type
10.4. Asia Pacific Somatostatin Analogs Market Size and Forecast, By Indication
10.5. Asia Pacific Somatostatin Analogs Market Attractiveness Index
10.6. Asia Pacific Somatostatin Analogs Market Attractiveness Index, By Country
10.7. Asia Pacific Somatostatin Analogs Market Attractiveness Index, By Type
10.8. Asia Pacific Somatostatin Analogs Market Attractiveness Index, By Indication
11. MEA Somatostatin Analogs Market Analysis and Forecast, 2019–2029
11.1. Introduction
11.1.1. MEA Somatostatin Analogs Market
11.1.2. MEA Somatostatin Analogs Market, Annual Growth Rate Comparison, By Country
11.2. MEA Somatostatin Analogs Market Size and Forecast, By Country
11.2.1. GCC Somatostatin Analogs Market
11.2.2. South Africa Somatostatin Analogs Market
11.2.3. North Africa Somatostatin Analogs Market
11.2.4. Rest of MEA Somatostatin Analogs Market
11.3. MEA Somatostatin Analogs Market Size and Forecast, By Type
11.4. MEA Somatostatin Analogs Market Size and Forecast, By Indication
11.5. MEA Somatostatin Analogs Market Attractiveness Index
11.6. MEA Somatostatin Analogs Market Attractiveness Index, By Country
11.7. MEA Somatostatin Analogs Market Attractiveness Index, By Type
11.8. MEA Somatostatin Analogs Market Attractiveness Index, By Indication
12. Leading Companies in the Somatostatin Analogs Market
12.1. Competition Dashboard
12.2. Company Share Analysis
12.3. Company Profiling of 25 Major Players
12.3.1. Company Overview
12.3.2. Segment 1 Offerings
12.3.3. Financial Performance (2016-2018)
12.3.4. Recent Initiatives
12.3.5. Average Gross Margin (2016-2018)
13. Conclusion
14. Glossary
List of Figures
15.1. Research design
15.2. Market segmentation & scope
15.3. Value chain analysis
15.4. Porter’s Five Forces
15.5. Market summary
15.6. Market driver analysis (Current & Future Impact)
15.7. Market restraint analysis (Current & Future Impact)
15.8. Global Somatostatin Analogs Market by Type, 2019-2029 (USD million)
15.9. Global Somatostatin Analogs Market for Octreotide, 2019-2029 (USD million)
15.10. Global Somatostatin Analogs Market for Lanreotide, 2019-2029 (USD million)
15.11. Global Somatostatin Analogs Market for Pasireotide, 2019-2029 (USD million)
15.12. Global Somatostatin Analogs Market by Indication, 2019-2029 (USD million)
15.13. Global Somatostatin Analogs Market for Neuroendocrine Tumor (NET), 2019-2029 (USD million)
15.14. Global Somatostatin Analogs Market for Acromegaly, 2019-2029 (USD million)
15.15. North America Somatostatin Analogs Market by Type, 2019-2029 (USD million)
15.16. North America Somatostatin Analogs Market for Octreotide, 2019-2029 (USD million)
15.17. North America Somatostatin Analogs Market for Lanreotide, 2019-2029 (USD million)
15.18. North America Somatostatin Analogs Market for Pasireotide, 2019-2029 (USD million)
15.19. North America Somatostatin Analogs Market by Indication, 2019-2029 (USD million)
15.20. North America Somatostatin Analogs Market for Neuroendocrine Tumor (NET), 2019-2029 (USD million)
15.21. North America Somatostatin Analogs Market for Acromegaly, 2019-2029 (USD million)
15.22. Latin America Somatostatin Analogs Market by Type, 2019-2029 (USD million)
15.23. Latin America Somatostatin Analogs Market for Octreotide, 2019-2029 (USD million)
15.24. Latin America Somatostatin Analogs Market for Lanreotide, 2019-2029 (USD million)
15.25. Latin America Somatostatin Analogs Market for Pasireotide, 2019-2029 (USD million)
15.26. Latin America Somatostatin Analogs Market by Indication, 2019-2029 (USD million)
15.27. Latin America Somatostatin Analogs Market for Neuroendocrine Tumor (NET), 2019-2029 (USD million)
15.28. Latin America Somatostatin Analogs Market for Acromegaly, 2019-2029 (USD million)
15.29. Western Europe Somatostatin Analogs Market by Type, 2019-2029 (USD million)
15.30. Western Europe Somatostatin Analogs Market for Octreotide, 2019-2029 (USD million)
15.31. Western Europe Somatostatin Analogs Market for Lanreotide, 2019-2029 (USD million)
15.32. Western Europe Somatostatin Analogs Market for Pasireotide, 2019-2029 (USD million)
15.33. Western Europe Somatostatin Analogs Market by Indication, 2019-2029 (USD million)
15.34. Western Europe Somatostatin Analogs Market for Neuroendocrine Tumor (NET), 2019-2029 (USD million)
15.35. Western Europe Somatostatin Analogs Market for Acromegaly, 2019-2029 (USD million)
15.36. Eastern Europe Somatostatin Analogs Market by Type, 2019-2029 (USD million)
15.37. Eastern Europe Somatostatin Analogs Market for Octreotide, 2019-2029 (USD million)
15.38. Eastern Europe Somatostatin Analogs Market for Lanreotide, 2019-2029 (USD million)
15.39. Eastern Europe Somatostatin Analogs Market for Pasireotide, 2019-2029 (USD million)
15.40. Eastern Europe Somatostatin Analogs Market by Indication, 2019-2029 (USD million)
15.41. Eastern Europe Somatostatin Analogs Market for Neuroendocrine Tumor (NET), 2019-2029 (USD million)
15.42. Eastern Europe Somatostatin Analogs Market for Acromegaly, 2019-2029 (USD million)
15.43. Asia Pacific Somatostatin Analogs Market by Type, 2019-2029 (USD million)
15.44. Asia Pacific Somatostatin Analogs Market for Octreotide, 2019-2029 (USD million)
15.45. Asia Pacific Somatostatin Analogs Market for Lanreotide, 2019-2029 (USD million)
15.46. Asia Pacific Somatostatin Analogs Market for Pasireotide, 2019-2029 (USD million)
15.47. Asia Pacific Somatostatin Analogs Market by Indication, 2019-2029 (USD million)
15.48. Asia Pacific Somatostatin Analogs Market for Neuroendocrine Tumor (NET), 2019-2029 (USD million)
15.49. Asia Pacific Somatostatin Analogs Market for Acromegaly, 2019-2029 (USD million)
15.50. MEA Somatostatin Analogs Market by Type, 2019-2029 (USD million)
15.51. MEA Somatostatin Analogs Market for Octreotide, 2019-2029 (USD million)
15.52. MEA Somatostatin Analogs Market for Lanreotide, 2019-2029 (USD million)
15.53. MEA Somatostatin Analogs Market for Pasireotide, 2019-2029 (USD million)
15.54. MEA Somatostatin Analogs Market by Indication, 2019-2029 (USD million)
15.55. MEA Somatostatin Analogs Market for Neuroendocrine Tumor (NET), 2019-2029 (USD million)
15.56. MEA Somatostatin Analogs Market for Acromegaly, 2019-2029 (USD million)
15.57. List of Companies
List of Tables
16.1. Global Somatostatin Analogs Market, by Type, 2019-2029 (USD million)
16.2. Global Somatostatin Analogs Market, by Indication, 2019-2029 (USD million)
16.3. North America Somatostatin Analogs Market, 2019-2029 (USD million)
16.4. U.S. Somatostatin Analogs Market, 2019-2029 (USD million)
16.5. Canada Somatostatin Analogs Market, 2019-2029 (USD million)
16.6. Latin America Somatostatin Analogs Market, 2019-2029 (USD million)
16.7. Brazil Somatostatin Analogs Market, 2019-2029 (USD million)
16.8. Mexico Somatostatin Analogs Market, 2019-2029 (USD million)
16.9. Rest of Latin America Somatostatin Analogs Market, 2019-2029 (USD million)
16.10. Western Europe Somatostatin Analogs Market, 2019-2029 (USD million)
16.11. UK Somatostatin Analogs Market, 2019-2029 (USD million)
16.12. France Somatostatin Analogs Market, 2019-2029 (USD million)
16.13. Germany Somatostatin Analogs Market, 2019-2029 (USD million)
16.14. Italy Somatostatin Analogs Market, 2019-2029 (USD million)
16.15. Nordic Somatostatin Analogs Market, 2019-2029 (USD million)
16.16. Benelux Somatostatin Analogs Market, 2019-2029 (USD million)
16.17. Rest of Western Europe Somatostatin Analogs Market, 2019-2029 (USD million)
16.18. Eastern Europe Somatostatin Analogs Market, 2019-2029 (USD million)
16.19. Russia Somatostatin Analogs Market, 2019-2029 (USD million)
16.20. Poland Somatostatin Analogs Market, 2019-2029 (USD million)
16.21. Rest of Eastern Europe Somatostatin Analogs Market, 2019-2029 (USD million)
16.22. Asia Pacific Somatostatin Analogs Market, 2019-2029 (USD million)
16.23. Japan Somatostatin Analogs Market, 2019-2029 (USD million)
16.24. India Somatostatin Analogs Market, 2019-2029 (USD million)
16.25. Australia Somatostatin Analogs Market, 2019-2029 (USD million)
16.26. ASEAN Somatostatin Analogs Market, 2019-2029 (USD million)
16.27. China Somatostatin Analogs Market, 2019-2029 (USD million)
16.28. Rest of Asia Pacific Somatostatin Analogs Market, 2019-2029 (USD million)
16.29. MEA Somatostatin Analogs Market, 2019-2029 (USD million)
16.30. South Africa Somatostatin Analogs Market, 2019-2029 (USD million)
16.31. North Africa Somatostatin Analogs Market, 2019-2029 (USD million)
16.32. GCC Somatostatin Analogs Market, 2019-2029 (USD million)
16.33. Rest of MEA Somatostatin Analogs Market, 2019-2029 (USD million)
Chiasma, Inc.
Ipsen Biopharmaceuticals, Inc.
Novartis AG
Peptron
SomaDex
Sun Pharma Advanced Research Company Ltd.